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Non-aerobic resting metabolic rateRisperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-
induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type fe-
male C57BL/6Jmice treatedwith risperidone (80 μg/day) exhibited signiﬁcant excessweight gain, due to reduced
energy expenditure, which correlatedwith an altered gutmicrobiome. Fecal transplant from risperidone-treated
mice caused a 16% reduction in total restingmetabolic rate in naïve recipients, attributable to suppression of non-
aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than
those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufﬁ-
cient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively,
these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone,
and speciﬁcally implicates the modulation of non-aerobic resting metabolism in this mechanism.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent studies associate the gut microbiome, the bacterial ecosys-
tem that resides in the human gut, with the modulation of weight
gain and metabolic diseases. It has been shown that the microbiome
contributes to host metabolism and physiology by several mechanisms
including increased energy harvest from the diet (Turnbaugh et al.,
2006, 2008), modulation of lipid metabolism (Bäckhed et al., 2004;
Velagapudi et al., 2010), altered endocrine function (Dumas et al.,
2006; Swann et al., 2011;Wang et al., 2011), and inﬂammatory stability
(Elinav et al., 2011; Hall et al., 2011; Henao-Mejia et al., 2012;
Vandanmagsar et al., 2011). Thus the gut microbiota is inﬂuential in
modulating obesity and other metabolic diseases.
Contributing to the obesity epidemic over the last two decades,
the prescribing rate of second-generation antipsychotics for children
has increased nearly eight-fold due to their efﬁcacy (Findling et al.,gy, 51 Newton Rd., 3-632 BSB,
. This is an open access article under2005). Second generation antipsychotics (SGAs) are used to treat a vari-
ety of psychiatric illnesses, including autism, bipolar disorder and
schizophrenia. It has also beenwell established that themost commonly
prescribed SGA, risperidone (a benzylamino-piperidine derivative),
causes signiﬁcant weight gain, insulin resistance, and metabolic syn-
drome (Möller et al., 2015; Calarge et al., 2012; Correll et al., 2009; De
Hert et al., 2011). Numerous observational studies of risperidone-
induced weight gain have led to signiﬁcant advancements in treatment
guidelines. However, the multifactorial nature of cardiometabolic ef-
fects is not completely understood, and patients taking risperidone
still suffer from the side effects associated with weight gain. In humans,
risperidone may promote weight gain through appetite stimulation, al-
thoughmany animal studies comparing SGAs challenge this hypothesis
(Baptista et al., 2004; F. Li et al., 2013; Pouzet et al., 2003; Smith et al.,
2012). Risperidone-induced weight gain is thought to be multifaceted,
involving genetic, metabolic, and environmental contributors (Correll
et al., 2011; Lett et al., 2011). Recent data implicates alterations in the
gut microbiome as the mechanism by which SGAs impact metabolism
and weight gain (Davey et al., 2013; Morgan et al., 2014). We have ev-
idence that alterations in the gut microbiome of children chronicallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pared to antipsychotic-naïve children (Bahr et al., 2015).
In this study, we examined the hypothesis that shifts in the gut
microbiome are mechanistically linked to weight gain that occurs in
response to risperidone treatment. We examined energy balance
andweight gain in wild typemice in response to treatmentwith risper-
idone alone or in combination with various xenobiotics, transfer of
risperidone-altered microbiota, or transfer of the phage associated
with risperidone-treated microbiota. We found that risperidone alters
the gut microbiota resulting in weight gain via suppressed energy ex-
penditure. Furthermore, transfer of risperidone-treated fecal material,
including the phage fraction alone, was sufﬁcient to induce similar ef-
fects in naïvemice. Identiﬁcation of the gutmicrobiome as a critical me-
diator of energy homeostasismay identify novel therapeutic targets and
approaches for risperidone-induced weight gain and obesity.
2. Materials and methods
2.1. Animal husbandry
Six to seven-week old C57BL/6J female mice from the Jackson Labo-
ratory were housed in a standard 12:12 dark–light cycle with ad libitum
access to standard chow (Teklad 7013; 18% kcal from fat) and water
(pH 3.7 with acetic acid to match the pH of oral risperidone) or water
with risperidone (20 μg/ml, pH 3.7). Antibiotics were administered for
ten days in drinking water at 62.5 mg/l and 142.5 mg/l of ciproﬂoxacin
and ampicillin respectively. All procedures were approved by the
University of Iowa Animal Care and Use Committee in compliance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
2.2. Nuclear magnetic resonance
Body composition was assessed using nuclear magnetic resonance
(NMR; Brucker LF90II). Mice were restrained (b1 min) for analysis
and then returned to home cages.
2.3. Energy intake
Mice were individually housed in metabolic cages (Nalgene) to
monitor ﬂuid and food intakedaily. Additionally, urine and fecal outputs
were measured and collected. Fecal material was utilized to determine
digestive efﬁciency by bomb calorimetry.
2.4. Bomb calorimetry
Caloric densities of desiccated food and fecal samples were deter-
mined using a 50 mg semi-micro bomb calorimeter (Parr). Energy
absorption was calculated as:
Energy Absorbed½  ¼ Energy Consumed½ − Fecal Energy½ :
Energy Consumed is the product of the dry mass of food consumed
and the caloric density of dry food, and Fecal Energy is the product of
the dry mass of feces produced and the caloric density of the dried
feces. Digestive efﬁciency was then calculated as:
Digestive Efficiency½  ¼ Energy Absorbed½ 
Energy Consumed½  :
Energy efﬁciency was calculated at various time points after the ini-
tiation of risperidone as:
Energy Efficiency½  ¼ Δ Body Mass½ X
Energy Absorbed
h i :2.5. Physical activity & core temperature
Physical activity and core temperature were determined using ra-
diotelemetric probes (DSI), as previously described (Burnett and
Grobe, 2014; Grobe et al., 2010). Mice were anesthetized using
isoﬂurane and probes were inserted inside the abdominal wall. Follow-
ing 1–2weeks of recovery, activity and core temperaturewere recorded
for 30 s every 5 min throughout the light–dark cycle (Fig. S1).
2.6. Combined calorimetry
Resting metabolic rate (RMR) was measured simultaneously by di-
rect calorimetry and respirometry as previously described (Burnett
and Grobe, 2013, 2014). Brieﬂy, rates of total heat dissipation, heat
retention, and O2 and CO2 exchange of mice were assessed during
sleep at thermoneutrality (30 °C) respectively, using a custom-built
gradient-layer direct calorimeter, core temperature telemeters (DSI)
and S-3A/II O2 and CD-3A CO2 analyzers (AEI). Mass ﬂow of air was
measured (Sensiron) and STP-corrected. Total RMR determined by di-
rect calorimetry represents the sum of all heat dissipation (sensible
and insensible) plus heat retained,which is determined by core temper-
ature change and body composition as determined using NMR. Aerobic
RMR determined by respirometry represents the estimated heat pro-
duction using the formula derived from Lusk (1924):
Aerobic RMR½  ¼ VO2 1:232 RER þ 3:815ð Þ:
VO2 represents STP-corrected rate of oxygen consumption (in
ml/min), and the respiratory exchange ratio, RER, represents the ratio
of carbon dioxide production to oxygen consumption. Non-aerobic
RMR represents the difference betweenmeasured total heat production
(from direct calorimetry) and the estimated rate of aerobic RMR (from
respirometry):
Total RMR½  ¼ Aerobic RMR½  þ Non−Aerobic RMR½ 
It is important to note that throughout the current study, we report
“RMR” data from mice, assessed while the animals are sleeping. The
metabolic rate during sleep is more accurately referred to as “sleeping
metabolic rate, SMR” but given the complexities of dissociating resting
vs. sleeping metabolic rates in mice, few reports in the literature use
this terminology in studies examining metabolic function in mice. In
contrast, in humans SMR and RMR are clearly distinct. Thus although
less technically accurate, we have chosen to report data herein as
“RMR” instead of “SMR” as a reﬂection of the current vernacular of the
ﬁeld.
2.7. Bacterial DNA extraction and sequencing
16S rRNA gene sequencing methods were adapted from the methods
developed for the NIH-Human Microbiome Project (Consortium, 2012).
Brieﬂy, bacterial genomic DNA was extracted using MO BIO PowerSoil
DNA Isolation Kit (MO BIO Laboratories). The 16S rDNA V4 region was
ampliﬁed by PCR and sequenced on the MiSeq platform (Illumina)
using the 2 × 250 bp paired-end protocol yielding pair-end reads. The
primers used for ampliﬁcation contain adapters for MiSeq sequencing
and dual-index barcodes so that the PCR products may be pooled and
sequenced directly (Caporaso et al., 2012) targeting at least 6000
reads per sample.
2.8. Sequencing analysis
16S data was analyzed using QIIME v.1.9 software. Barcodes were
matched to fastq ﬁles and then removed (Caporaso et al., 2010b).
Similar sequences (cutoff 97%) were combined into operational taxo-
nomic units (OTU) using sumaclust v1.1.00 and sortmerna 2.0.
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(Caporaso et al., 2010a). The lanemaskPH was used to screen out the
hypervariable regions and OTUs were classiﬁed with the greengenes
database (DeSantis et al., 2006). Observed species, Chao1, and phyloge-
netic diversity metrics were assessed with alpha_diversity.py and
compare_alpha_diversity.py in QIIME. Samples were rareﬁed to a
depth of 6000 sequences/sample, which was shown to be sufﬁcient by
goods coverage. Beta diversity was assessed using UniFrac in QIIME
(Lozupone et al., 2010). LEfSe was usedwith default parameters on spe-
cies level OTU tables to determine taxa that best characterize each pop-
ulation (Segata et al., 2011). Only features with LDA scores N2.0 were
kept.
2.9. Fecal transfer
Fecal material (0.3 g) from respective donor cohorts was collected
andpooled, groundby sterilemortar and pestle and suspended in sterile
water (1ml/0.1 g stool). Sampleswere centrifuged for 2min at 3000 ×g
to remove large particulates. Individual mice received 100 μl of respec-
tive fecal supernatant by oral gavage daily for 14 consecutive days.
2.10. Risperidone measurement by HPLC–MS
Risperidone and 9-hydroxyrisperidone were dissolved in a mixture
of water and methanol (1:1) to a concentration of 1 mg/ml and subse-
quently diluted with the same diluents to 10 mcg/ml, 1 mcg/ml and
100 ng/ml in order to prepare standards and controls for the calibration
curve. Calibration standards were prepared by adding between 5 and
25 μl of the appropriate working standard to 0.5 ml water to make
nine standards between 1 and 500 ng/ml. The concentrations of control
samples were 3, 75 and 300 ng/ml. Internal standard solution was pre-
pared by dissolving clozapine in methanol:water 1:1 to a concentration
of 1 mcg/ml. The homogenized fecal samples, standards, blanks and
controls were spiked with 50 μl of the internal standard and diluted
with 500 μl of 4% H3PO4 in water. All samples were vortexed and sub-
jected to solid phase extraction (SPE) prior to instrumental analysis.
SPE was conducted using Oasis MCX cartridges (Waters Inc.). The SPE
cartridges were conditioned with 1 ml of methanol and 1 ml of
nanopure water. The samples were loaded into SPE cartridges and
rinsed with 1 ml of 2% formic acid in water, followed by 1 ml of metha-
nol. Then the samples were eluted with 1 ml of 5% ammonium hydrox-
ide in methanol and then dried under nitrogen ﬂow. The samples
were reconstitutedwith 200 μl of 0.1% formic acid inwater and acetoni-
trile mixture (1:1) and injected (15 μl) into an HPLC–MS (Shimadzu
2010A LC–MS platform in APCI ion mode operating under LCMS Solu-
tion software Version 2.04H3, Shimadzu, Columbia, MD, USA). A
Phenomenex Synergi Polar RP analytical column (4 μm, 2 × 250 mm,
Phenomenex, Torrance, CA) preceded by a Phenomenex Hydro PR 80A
column was used for chromatographic separation of risperidone, 9-
hydroxyrisperidone and clozapine (internal standard). Isocratic analysis
was performed at 0.2 ml/min ﬂow rate. Mobile phase consisted of 0.1%
formic acid in water and acetonitrile (38:65). The mass spectrometer
was tuned using a polyethylene glycol solution following the
manufacturer's protocol. The scan interval was 0.3 s, microscan —
0.1 amu, APCI temperature was 400 °C, the CDL temperature was
200 °C, and the heat block temperature was 200 °C. Nitrogen ﬂow rate
was 2.5 L/min; detector voltage was 1.5 kV. The monitored mass-to-
charge ratio was 427.4 for risperidone, 411.4 for 9-hydroxyrisperidone
and 327.1 for clozapine. The assay was linear from 1 to 500 ng/ml and
the coefﬁcient of variation was b15% for all control samples.
2.11. Phage isolation and transfer
Bacteriophage were isolated from stool as previously described
(Thurber et al., 2009). Brieﬂy, approximately 5 g of mouse stool was
pooled from ﬁve treated or control mice over a 24 h time course. Stoolwas homogenized in PBS using amortar and pestle andwas centrifuged
at 3000 ×g for 3 min. Supernatant was collected and the pellet was ho-
mogenized in PBS to collect supernatant twice more. Total collected su-
pernatant was ﬁltered through 0.45 μm and 0.22 μm ﬁlters and then
added to a gradient containing 1.75 g/ml, 1.55 g/ml, and 1.35 g/ml den-
sities of CsCl. Gradients were spun at 60,000 ×g for 2 h at 4 °C. Approx-
imately 2ml of bacteriophagewere generated from each 50ml gradient
by inserting a 20-gauge needle into the 1.75 g/ml layer and drawing out
the phage fraction. Pooled phage fractions were dialyzed to remove re-
sidual CsCl. Phage particles were assessed using an epiﬂourescent mi-
croscope after viral particles had been stained with SYBR-gold. This
allowed us to document the presence of bacteriophage and absence of
bacterial and/or eukaryotic cells. Pooled phage were aliquoted into
350 μl fractions for daily use to be combined in a 1:1 ratio by volume
with rehydrated milk. Individual mice received 50 μl of respective
phage fraction with 50 μl of milk by oral gavage daily for 4 weeks.
2.12. Growth of aerobic and anaerobic organisms
A freshly collected mouse fecal sample was homogenized with
1 × PBS for 10 min followed by centrifugation at 3000 ×g for 3 min to
remove debris. Organisms were grown aerobically and anaerobically
overnight at 37 °C in BPRM broth. Suppressive effects of risperidone
upon aerobic and anaerobic culture growth rates were determined
after 5 h of treatment. Optical densities (OD600) of cultures were nor-
malized against the growth exhibited by vehicle-treated cultures in
matched aerobic/anaerobic conditions, and IC50 concentrations were
calculated in SigmaPlot 13 by performing four-parameter logistic
curve ﬁtting using the following formula:
y ¼ minimumþ maximum−minimumð Þ
1þ xIC50
 −Hillslope :
Regressions for aerobic and anaerobic cultureswere reachedwith 11
and 8 iterations, with R2 values of 0.9876 and 0.9985, resulting in IC50
values of 77 ± 2 and 38 ± 1 μg/ml risperidone, and Hillslopes of
−5.13 ± 0.64 and−2.99 ± 0.17, respectively.
2.13. Statistics
Analyses of phyla level relative abundances were performed by
multiple t-test comparison. Analyses of genus relative abundance over
time, and behavioral and physiological endpoints were performed
using ANOVA with repeated measures as appropriate, followed by
Tukey multiple-comparisons procedures. Signiﬁcance was assigned as
p b 0.05, and data are reported as mean ± sem throughout.
3. Results
3.1. Risperidone treatment results in increased weight gain that correlates
with an altered gut microbiome
To better understand the role of the gut microbiota in the develop-
ment of risperidone-induced weight gain, we conducted a prospective
study on individually housed C57BL/6J mice over two months.
Risperidone was provided in drinking water at 20 μg/ml. On average,
mice consumed 4.1 ± 0.3 ml/day, which thereby resulted in an average
80 μg/day risperidone treatment. During risperidone treatment (n= 5)
or treatment with acidiﬁed water to match the acidity of oral risperi-
done (pH = 3.5, n = 5), body masses were assessed daily, and fecal
samples were collected weekly. By the sixth week, a signiﬁcant increase
inweightwas observed for thosemice exposed to risperidone, resulting
in a 2.8-g difference relative to the control mice. In contrast, mice were
offered a 1000-fold lower dose of risperidone (20 ng/ml in drinking
water resulting in consumption of 80 ng/day) and exhibited normal
1728 S.M. Bahr et al. / EBioMedicine 2 (2015) 1725–1734rates of growth (Fig. 1A–B). This broadly establishes a dose-dependence
for risperidone to cause weight gain and thus provides a rationale to
treat mice with 20 μg/ml in subsequent studies.
Next, we analyzed the composition of the gut microbiota by 16S
rDNA sequencing. The composition of the gutmicrobiome ofmice treat-
ed with risperidone (20 μg/ml) for 58 days was signiﬁcantly different
than the microbiome for control mice (ANOSIM R = 0.8954, p =
0.002) (Fig. 1C–D). Risperidone treated mice had a 32.6% increase in
the relative abundance of Firmicutes with a reciprocal 22.4% decrease
in the relative abundance of Bacteroidetes, two major phyla found in
the gut microbiome (p b 0.05, Fig. S2) (Consortium, 2012). Within the
phylum Bacteroidetes, the most abundant genera represented in either
treatment group were the Bacteroides and Alistipes. Bacteroides spp.
weremore abundant following risperidone treatment compared to con-
trol mice (p b 0.05, Fig. 1E). Conversely, Alistipes spp. were consistently
more abundant in controls compared to risperidone treated mice
(p b 0.05, Fig. 1F). Within the phylum Firmicutes, Lactobacillus spp.
were more abundant in controls compared to risperidone treated mice
(p b 0.05, Fig. 1G). The most abundant genera found within risperidone
treated mice were Allobaculum spp., with a very large increase, 36.5%,
relative to controls (p b 0.05, Fig. 1H). Additional organisms were iden-
tiﬁed that differentiate the risperidone treated microbiota relative to
controls as determined by LDA effect size analysis with LEfSe (Fig. 1I).
Collectively, these organisms represent statistically signiﬁcant discrimi-
natory operational taxonomic units (OTUs) for risperidone treatment in
mice.
3.2. Bodymass gains inmice treatedwith risperidone are due to suppressed
energy expenditure
To understand themechanism ofweight gain inmice induced by ris-
peridone, we assessed total energy ﬂux using bomb calorimetry (Fink
et al., 2014). Nine weeks of risperidone treatment led to a 2.51 g in-
crease in body weight (Fig. 2A, p b 0.05). Food intake behavior for
C57BL/6Jmicewas found to be similar between groups, resulting in nor-
mal daily caloric ingestion, as reported previously for risperidone (Fig.
2B) (Baptista et al., 2004; X. Li et al., 2013; Pouzet et al., 2003; Smith
et al., 2012). Similarly, risperidone treatment had no effect on digestive
efﬁciency (Fig. 2C). Thus, with similar intake and efﬁciency, total daily
caloric absorption was similar between groups (Fig. 2D). Energy
efﬁciency, the rate of weight gain per unit energy absorbed, was
signiﬁcantly greater with risperidone treatment for the ﬁrst few
weeks of treatment, reﬂecting a reduction in energy expenditure com-
pared to controls (Fig. 2E). We then determined that total resting met-
abolic rate did not increase despite gains in body mass following
risperidone treatment (Figs. 2F, S3). Thus, we conclude that excess
weight gain in mice following risperidone treatment occurs through
suppressed energy expenditure, attributable to an altered restingmeta-
bolic rate.
3.3. Other xenobiotics do not prevent risperidone-induced weight gain
We hypothesized that synergistic or opposing shifts in the
microbiome initiated through administering xenobiotics in addition to
risperidone would alter energy expenditure and resulting weight gain.
To test this possibility, we treated unique cohorts of mice with ampicil-
lin, ciproﬂoxacin, and risperidone, alone or in combination, resulting in
consumption of 0.54 mg, 0.24 mg, and 80 μg per day respectively. AllFig. 1. Chronic risperidone treatment results in increased weight gain and an altered microbio
masseswere assessed daily in 10 C57BL/6 femalemicemaintained on standard chowwith ad lib
were assessed during risperidone treatment at a 1000-fold lower dose of risperidone (20 ng/m
community structure after treatmentwith risperidone. Day 0 (Gray), Day 58 risperidone (red), a
byANOSIM (R=0.895, p=0.002). D)Mean pairwise intra- and intergroupUniFrac distances o
E–H) Genus-level percent relative abundances of the microbiome during treatment with r
I) Discriminatory OTUs among treatment populations as determined by LEfSe analysis.mice were treated with either risperidone or acidiﬁed water for
48 days. Antibiotic administration began on the 10th day and continued
for 10days. Risperidone treatment led to a 2.80 gweight increase by day
48, while ten-day courses of antibiotics did not signiﬁcantly change the
outcome of weight gain (Fig. 3A). Food intake behavior and digestive
efﬁciency were found to be similar among all treatment groups
(Fig. 3B–C). Additionally, energy absorption was unchanged following
antibiotic perturbation (Fig. 3D). We conclude that while other xenobi-
otics cause unique shifts in the gut microbiome which can synergize
with risperidone (Fig. 3E), risperidone alone is sufﬁcient to reduce ener-
gy expenditure and induceweight gain. These results provide additional
support for the conclusion reached above, namely that risperidone-
induced weight gain occurs speciﬁcally through suppressed energy
expenditure.
3.4. Risperidone differentially suppresses anaerobic growth of cultured gut
microorganisms
Based on its molecular structure and effects on the microbiome
(Figs. 1I and 3E), we hypothesized that risperidone may directly
affect the growth of organisms within the gut. To test this possibility,
microorganisms collected from fresh stool were grown overnight
under either aerobic or anaerobic conditions. Increasing concentrations
of risperidonewere shown to inhibit the growth of organisms (Fig. 4A).
The concentration of risperidone required to inhibit growth of
aerobes was greater than the dose needed to suppress the growth of
anaerobes (Fig. 4B). After 5 h of growth with risperidone, the IC50 for
aerobes was 77 ± 2 μg/ml while the IC50 for anaerobes was 38 ±
0.4 μg/ml (Fig. 4C, p b 0.05). These data demonstrate that risperidone
is capable of suppressing the growth of microorganisms cultured from
the gut and that anaerobically growing bacteria display increased sensi-
tivity to risperidone. These data suggest that risperidone could act di-
rectly on gut microbes to produce shifts in the microbiome described
above.
3.5. Fecal transfer of risperidone-treated microbiota into naïve recipients
suppresses non-aerobic resting metabolic rate
The results above led to the hypothesis that risperidone-altered mi-
crobiota are responsible for the associated weight gain in treated ani-
mals. To establish Koch's third postulate and attribute risperidone-
induced weight gain to the gut microﬂora and consequent energy ex-
penditure, we performed a fecal transfer from either vehicle- (n = 3)
or risperidone-treated mice (n = 3) to a second cohort of naïve
mice (n = 6 vehicle recipients and n = 7 risperidone recipients)
(Fig. 5A). Transfer of the gut microbiota from vehicle-treated animals
had no effect on total resting metabolic rate (RMR), but transfer
from risperidone-treated microbiota caused a 16% reduction in total
RMR for recipients (Fig. 5B). Importantly, the reduction in total
RMR in mice receiving the transplant from a risperidone-treated
donor was due entirely to a reduction in non-aerobic RMR, while
transfer from risperidone-treated mice had no effect on aerobic RMR
(Figs. 5C, S4). Together, these results establish that the shift in the
microbiota caused by chronic exposure to risperidone is sufﬁcient to
cause the reduced energy expenditure described above. Lastly, a 16%
reduction in RMR is sufﬁcient to account for the observed weight gain
(see Discussion).me. For all panels, color indicates risperidone treatment (red) vs. control (blue). A) Body
itum access towater (n= 5) or water with risperidone (20 μg/ml, n= 5). B) Bodymasses
l, n = 5). C) PCoA of UniFrac distances illustrating the association between gut bacterial
nd Day 58 control (blue). RisperidoneDay 58 sampleswere compared to all other samples
f control and chronic RSP treatment at days 0 and 58. p b 0.05 based on 1000 permutations.
isperidone vs. controls over time. Data are representative of mean ± s.e.m. *p b 0.05.
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Fig. 2. Bodymass gains inmice treatedwith risperidone result from suppression of energy efﬁciency via resting metabolic rate. A) Bodymass gains were assessed daily in C57BL/6 female
micemaintained on standard chowwith ad libitum access towater (n=5) orwaterwith risperidone (20 μg/ml, n=5) for nineweeks. B) Food intake behaviorwasmeasured daily during
housing inmetabolic cages. C) Digestive efﬁciency was determined by bomb calorimetry, and performed on desiccated food and feces. D) Energy absorbed was calculated as the subtrac-
tion of calculated fecal energy fromenergy consumed. E) Energy efﬁciencywas calculated as the rate ofweight gain per unit energy absorbed. F) Total restingmetabolic rate,measured by direct
calorimetry, was assessed in mice after treatment with water (n = 4) or water with risperidone (20 μg/ml, n = 4) for two weeks. Data are representative of mean ± s.e.m. *p b 0.05.
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possibility that risperidone present in the stool may have been trans-
ferred directly to the recipient mice via gavage. Thus, we performed
HPLC to measure the amount of risperidone in stool from a donor
prior to fecal transfer by gavage. The HPLC analysis indicated that the
concentration of risperidone found in fecal samples was only 8.7 ±
1 ng/ml, corresponding to 0.87 ng delivered via gavage per day or
0.001% of the original dose received daily from drinking water. Thus,
the total amount of risperidone found in donor stool is 10-fold less
that that used to establish a dose–response curve above which pro-
duced no observable effects (Fig. 1B). Thus, we conclude that the
microbiota itself is the obesigenic factor present within the stool of
risperidone-treated mice.
3.6. Risperidone-treated phage fractions are capable of suppressing host
energy expenditure
In addition to bacteria, phage are also present within the gut (Minot
et al., 2012, 2013; Reyes et al., 2010). Phage genomes are known to
encode traits such as antibiotic resistance, which can be mobilized by
exposure to antibiotics and subsequently transferred to other organisms
(Modi et al., 2013). Thus, we considered the possibility that risperidone
treatment might alter the phageome in the mouse gut and could ulti-
mately affect the energy expenditure and subsequent weight gain for
the host.
To determine if bacteriophage play a contributing role in body mass
gain,we isolated phage from the stool of risperidone and vehicle treated
mice using methods described previously (Thurber et al., 2009)
(Fig. S5). Two unique cohorts of mice received a dose of 7 × 109 phage
particles (as estimated by microscopy) by gavage each day for 24
consecutive days either from risperidone (n=7) or control (n= 6) do-
nors. Transfer of phage isolated from risperidone-treatedmicrobiota re-
sulted in signiﬁcant weight gain relative to vehicle (p b 0.05) (Fig. 6A).
Furthermore, food intake behavior and digestive efﬁciency was un-
changed with phage treatment (Fig. 6B–C). Energy absorbed wastherefore also unchanged (Fig. 6D). Thus, we conclude that the phage
fraction induces changes in the gut microbiota resulting in decreased
energy expenditure, similar to that generated by risperidone treatment
alone.
4. Discussion
In this study, we demonstrate that risperidone causesmajor changes
in the gut microbiome and that those changes are mechanistically
linked to weight gain through the suppression of energy expenditure.
We demonstrate that suppression of energy expenditure is recapitulat-
ed via transfer of fecalmaterial or the phage fraction from a risperidone-
treated donor to a naïve recipient. Risperidone-induced suppression of
energy expenditure was not modiﬁed through addition of other
microbiome-altering xenobiotics. In parallel, we found that cultured
microorganisms from the gut were more sensitive to risperidone
when grown anaerobically than aerobically. The mechanism for sup-
pression of energy expenditure in vivo was found to be a reduction in
non-aerobic RMR following fecal transfer of the gut microbiota.
Therefore, host non-aerobic RMR can be suppressed by shifts in
the gut microbiome in response to treatment with risperidone.
Together, these ﬁndings highlight the critical role of the gut microbi-
ota in energy homeostasis and provide a potent example of the phys-
iological signiﬁcance of non-aerobic RMR in whole-animal energy
balance.
We used total calorimetry to assess the RMR of the subject, which
includes simultaneous measurement of total RMR via direct calorim-
etry, and aerobic RMR via respirometry (Kaiyala and Ramsay, 2011).
Simultaneous assessments of RMR in various species via direct
calorimetry and respirometry by our group and others have uncov-
ered large discrepancies (Walsberg and Hoffman, 2005, 2006;
Burnett and Grobe, 2013, 2014), which we interpret as an index of
non-aerobic processes. For example, we recently described a large
contribution (7 to 12%) of non-aerobic RMR in both C57BL/6J and
FVB/NCrl strains of mice (Burnett and Grobe, 2013, 2014). It is
Fig. 3. Additional xenobiotic-induced shifts in themicrobiome do not prevent risperidone-inducedweight gain through suppressed energy expenditure. 6-Week old female C57Bl/6mice
were maintained on standard chow with ad libitum access to water (n = 8) or risperidone (n = 8, 20 μg/ml) for 7 weeks. During the second week of treatment, all mice (n = 48) were
treated for 10 days with ampicillin (142.5 mg/l) or ciproﬂoxacin (62.5 mg/l). A) Bodymass gains were assessed daily. B) Food intake behavior wasmeasured during housing inmetabolic
cages during the seventhweek of treatment. C) Digestive efﬁciencywas determined through bomb calorimetry during the seventhweek of treatment. D) Energy absorbedwas calculated
as the subtraction of calculated fecal energy fromenergy consumed. E) PCoA of UniFrac distances illustrating the change in themicrobiomedue to risperidone treatment and the changes in
the microbiome due to antibiotic perturbation during the seventh week of treatment. Data are representative of mean ± s.e.m. *p b 0.05.
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even within a species. We also determined that one week of a 45%
high fat diet in C57BL/6J mice speciﬁcally suppresses non-aerobic
RMR (Burnett and Grobe, 2014). Because non-aerobic resting
metabolism exists in humans (Pittet et al., 1974, 1976), we are only
beginning to appreciate its physiological signiﬁcance (Burnett and
Grobe, 2014).
We also demonstrated that risperidone treatment led to an overall
reduction in observed taxa (OTUs) found within the gut microbiome
(Fig. S6) as well as selectively suppressing growth of organisms under
anaerobic conditions, similar to the environment foundwithin themam-
malian intestinal tract. The observed suppression of non-aerobic RMR
was found to be 16% of the total RMR for the animal. The magnitude of
this difference is substantial. For example, for a 2000 kcal/day human,
roughly 80% of total energy expenditure (1600 kcal/day) occurs in the
form of RMR. A 16% reduction in total RMR would therefore equate to
increasing energy retention by ~260 kcal/day, nearly equivalent to
consuming an extra standard McDonald's cheeseburger (290 kcal)
(McDonald's Nutrition, 2015) each day — a decidedly obesigenic
maneuver.Chronic treatment with risperidone led to speciﬁc alterations in
the microbiota. We found a signiﬁcant enrichment in Allobaculum
and Turicibacter spp., both members of the Firmicute family
Erysipelotrichaceae, which has been associated with diet-induced obe-
sity inmice (Ravussin et al., 2011). Interestingly, members of this family
have been shown in several independent studies to change in abun-
dance in response to dietary fat intake (Cani et al., 2008; Fleissner
et al., 2010; Turnbaugh et al., 2008). Aneroplasma spp., a member of
the Mollicutes class, was also found to be more abundant following ris-
peridone treatment. Previously, Gordon et al. performed metagenomic
sequencing and transcriptomics on diet-induced obesity cecal samples
of the microbiome, revealing that Mollicutes are enriched for pathways
involved in the import and fermentation of simple sugars and host
glycans (Turnbaugh et al., 2008) thereby providing a mechanism for
increased energy harvest from an obesigenic microbiota. We also
found a depletion of Alistipes spp. and Akkermansia spp. in risperidone
treated animals compared to controls, both of which have been
associated with a lean microbiota (Ridaura et al., 2013). Therefore, our
ﬁndings offer evidence that risperidone treatment alters the composi-
tion of the microbiome which suppresses resting metabolic rate
Fig. 4.Risperidonedifferentially suppresses growth of cultured gutmicroorganisms.Microorganismswere collected from stool and culturedeither aerobically or anaerobically overnight at
37 °C inBPRMbroth. A)Growth curves of aerobic and anaerobic organismswere determined in BPRMsupplementedwith risperidone at various concentrations. B)Differential growth due
to risperidone treatment is observed at the ﬁve hour timepoint. C) The IC50 of risperidone for anaerobic and aerobic growth was determined. Data are representative of mean ± s.e.m.
*p b 0.05.
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was conferred by the transfer of either the whole microbiota or the
phage fraction from risperidone treated mice, we propose that non-Fig. 5. Fecal transfer via gavage results in suppression of non-aerobic resting metabolic rates. A)
water (n= 4) orwaterwith risperidone (20mg/ml, n= 5) for nineweeks. Fecal material from
for control) daily for 14 days. Risperidone measured by HPLC in donor stool indicated that recip
aerobic RMR was measured in recipient mice. B) Total RMR in fecal transfer recipients. C) Com
metabolic rate. Data are representative of mean ± s.e.m. *p b 0.05.aerobic RMR is regulated in part by the gut microbiota. Therefore, ma-
nipulation of restingmetabolic rate, speciﬁcally via the gutmicrobiome,
represents a largely untapped approach to treating obesity. PreventingC57BL/6 female donor mice were maintained on standard chowwith ad libitum access to
donormicewas transferred by gavage to naive recipients (n= 7 for risperidone and n=6
ient mice received only 8.7 ± 1 ng/ml risperidone/day. Following fecal transfer, total and
bined calorimetry determined the aerobic and non-aerobic components of total resting
Fig. 6. Phage transfer via gavage results in increased bodymass without affecting digestive efﬁciency. Naïvemice were treated daily with bacteriophage isolated from risperidone-treated
mice (n = 7) or control (n = 6). A) Body mass gains were measured daily. B) Food intake behavior was measured during housing in metabolic cages. C) Digestive efﬁciency was deter-
mined through bomb calorimetry. D) Energy absorbed was calculated as the subtraction of calculated fecal energy from energy consumed. Data are representative of mean ± s.e.m.
*p b 0.05.
1733S.M. Bahr et al. / EBioMedicine 2 (2015) 1725–1734alteration of themicrobiome or the effects of the alteredmicrobiome on
RMR, may prove beneﬁcial for patients undergoing risperidone
treatment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.10.018.
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